- 7406 malaria professionals are enjoying the free benefits of MalariaWorld today

Who's online
There are currently 8 users and 266 guests online.
Online users
- Moon
- Sahithya
- machyman
- Sysadmin
- Dan Meshak
- DenisV
- ric.ataide
- nicoM
News Flash
Recent blog posts
- Where the real battle is won
- Amazing statements by leading malariologists
- How was malaria of 100 years ago eradicated in Palestine/Israel? And without vaccine?
- Winston Hide's courageous move
- Event: Symposium Malaria, maternal and infant health
- Job: Senior Lecturer / Lecturer in Epidemiology
- Job: Inspiring scientists in infectious tropical diseases
- Can we maintain effectiveness of the tools?
- Advertising on MalariaWorld
- Malaria elimination country briefings published by the UCSF Global Health Group
Active forum topics
- The role of community education and involvement in malaria control
- Introduce yourself to MalariaWorld members
- Fighting drug resistance by switching to environmental management of mosquito habitats
- Need for additional group to supplement WHO in fight against malaria
- Sustainable additions to WHO and PMI strategy
New forum topics
- Fighting drug resistance by switching to environmental management of mosquito habitats
- Grand Challemges Canada round 2. Help fund a malaria related project!
- Open Access 2.0:How to achieve this
- Pouring gasoline on the insecticide resistance fire?
- Need for additional group to supplement WHO in fight against malaria
The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis.
Plasmodium ovale malaria is currently a problem to diagnose in travellers, notably in French soldiers returning from the Ivory Coast.
This study demonstrates the efficacy and tolerability of AS + AQ for uncomplicated Plasmodium falciparum malaria treatment in African patients over the age of 7 years.
Raphael N’Guessan is a Medical Entomologist and West Africa 